Trinity Biotech (Trinity Biotech) FCF Margin % : -36.00% (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Trinity Biotech's Free Cash Flow for the three months ended in Sep. 2023 was $-5.28 Mil. Trinity Biotech's Revenue for the three months ended in Sep. 2023 was $14.68 Mil. Therefore, Trinity Biotech's FCF Margin % for the quarter that ended in Sep. 2023 was -36.00%.

As of today, Trinity Biotech's current FCF Yield % is -92.38%.

The historical rank and industry rank for Trinity Biotech's FCF Margin % or its related term are showing as below:

TRIB' s FCF Margin % Range Over the Past 10 Years
Min: -18.1 Med: -9.85 Max: 13.29
Current: -18.1

During the past 13 years, the highest FCF Margin % of Trinity Biotech was 13.29%. The lowest was -18.10%. And the median was -9.85%.

TRIB's FCF Margin % is ranked worse than
56.25% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.51 vs TRIB: -18.10

Trinity Biotech FCF Margin % Historical Data

The historical data trend for Trinity Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech FCF Margin % Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-10.47

-7.12

13.29

4.89

-9.22

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-4.13	2.48	-22.57	-35.85	-36.00

Competitive Comparison of Trinity Biotech's FCF Margin %

For the Diagnostics & Research subindustry, Trinity Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's FCF Margin % falls into.

Trinity Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Trinity Biotech's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-6.898	/	74.779
	=	-9.22 %

Trinity Biotech's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-5.284	/	14.677
	=	-36.00 %

Trinity Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.